2024-05-09 17:00 | UU:TARS | | News Release200 | Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference |
2024-05-08 16:05 | UU:TARS | | News Release200 | Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements |
2024-05-01 17:00 | UU:TARS | | News Release200 | Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 |
2024-04-23 08:30 | UU:TARS | | News Release200 | Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon |
2024-03-05 16:30 | UU:TARS | | News Release200 | Tarsus to Participate at Upcoming Investor Conferences |
2024-03-05 08:30 | UU:TARS | | News Release200 | Tarsus Introduces "Mite Party" Campaign for XDEMVY(TM) (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis |
2024-03-01 00:08 | UU:TARS | | News Release200 | Tarsus Announces Pricing of $100.0 Million Public Offering |
2024-02-29 16:38 | UU:TARS | | News Release200 | Tarsus Announces Proposed $100.0 Million Public Offering |
2024-02-27 06:00 | UU:TARS | | News Release200 | Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements |
2024-02-22 08:00 | UU:TARS | | News Release200 | Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept ¢ € œTick-Kill ¢ € Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease |
2024-02-20 17:00 | UU:TARS | | News Release200 | Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 |
2024-01-31 17:00 | UU:TARS | | News Release200 | Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference |
2023-12-11 08:00 | UU:TARS | | News Release200 | Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 ‚ for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites |
2023-11-09 16:05 | UU:TARS | | News Release200 | Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements |
2023-11-01 18:35 | UU:TARS | | News Release200 | Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 |
2023-09-06 08:00 | UU:TARS | | News Release200 | Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY ¢ „ ¢, the First and Only FDA Approved Treatment for Demodex Blepharitis |
2023-08-30 16:30 | UU:TARS | | News Release200 | Tarsus to Present at Upcoming Investor Conferences |
2023-08-24 09:00 | UU:TARS | | News Release200 | Now Available ¢ € “ XDEMVY ¢ „ ¢ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis |
2023-08-10 16:05 | UU:TARS | | News Release200 | Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements |
2023-08-01 22:31 | UU:TARS | | News Release200 | Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock |
2023-07-31 16:30 | UU:TARS | | News Release200 | Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock |
2023-07-25 07:00 | UU:TARS | | News Release200 | FDA Approves XDEMVY ¢ „ ¢ ‚ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis |
2023-06-12 08:30 | UU:TARS | | News Release200 | Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis |
2023-06-05 08:30 | UU:TARS | | News Release200 | Tarsus to Present at the Jefferies Global Healthcare Conference |